| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $23,810 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Marks Peter Ashley | director | 1 | $23,810 | 0 | $0 | $23,810 |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology …
Over the last 12 months, insiders at Alterity Therapeutics Limited have bought $23,810 and sold $0 worth of Alterity Therapeutics Limited stock.
On average, over the past 5 years, insiders at Alterity Therapeutics Limited have bought $23,810 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Marks Peter Ashley (director) — $23,810.
The last purchase of 47,620 shares for transaction amount of $23,810 was made by Marks Peter Ashley (director) on 2026‑08‑31.
| 2026-08-31 | Marks Peter Ashley | director | 47,620 0.0293% | $0.50 | $23,810 | -23.16% |
| Increased Positions | 5 | +22.73% | 2,102 | +0.63% |
| Decreased Positions | 7 | -31.82% | 11,646 | -3.48% |
| New Positions | 4 | New | 861 | New |
| Sold Out Positions | 2 | Sold Out | 178 | Sold Out |
| Total Postitions | 20 | -9.09% | 325,058 | -2.85% |